Dr. Gordon will have oversight over the SRF’s global clinical trial program CONQUEST and will contribute to the research program across the SRF portfolio San Francisco, CA (January 25, 2024)…
Read More
In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing...
Read More
FDA clears IND to launch CONQUEST trial platform with initial focus on Interstitial Lung Disease Secondary to Scleroderma (SSc-ILD) SCLERODERMA RESEARCH FOUNDATION (SRF) holds the IND as trial Sponsor Sanofi...
Read More
In our last eNews of the year, read about exciting research updates, like how CONQUEST has recieved the FDA's OK to proceed, and how CONQUER has already result in 6...
Read More
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
What makes researchers so dedicated to finding a cure? SRF-Funded investigator, Dr. Howard Chang of Stanford University, shares his perspective on making an impact through scleroderma research.
Read More
Lorena was diagnosed with scleroderma in 2021, and she wants a cure found for this disease. “When I went to see my scleroderma doctor for the first time, I was…
The most important part of this eNews? We're grateful for YOU! In our Thanksgiving edition, read more about how Cool Comedy • Hot Cuisine is helping us move research forward,...
Read More
In this month's eNews, learn more about the first-ever recipient of the Bob Saget Legacy Award, the new industry partner joining the CONQUEST platform clinical trial, a golfing fundraiser for...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
